Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted Recombinant Human Hepatocyte Growth Factor (KP-dHGF)), in Subjects With Venous Leg Ulcers

NCT00797706 is registered in ClinicalTrials.gov with Kringle Pharma Europe AB as lead sponsor.

NCT NCT00797706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00797706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted Recombinant Human Hepatocyte Growth Factor (KP-dHGF)), in Subjects With Venous Leg Ulcers
Lead sponsor
Kringle Pharma Europe AB
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 30, 2008
Completion date
March 31, 2010
Enrollment
75 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic venous leg ulcers